Distribution of mucosal PD-1 expressing T cells in patients with colitis of different etiologies. (3rd June 2021)

• Record Type: Journal Article
• Authors: Roosenboom, Britt; Horjus Talabur Horje, Carmen S.; Smids, Carolijn; Leeuwis, Jan Willem; van Koolwijk, Elly; Groenen, Marcel J. M.; Wahab, Peter J.; van Lochem, Ellen G.
• Is Part Of: Scandinavian journal of gastroenterology. Volume 56:Number 6(2021)
• Page Start: 671
• Page End: 679
• Publication Date: 2021-06-03
• Subjects: IBD -- PD-L1 -- therapy -- T cells -- immunotherapy-related colitis; Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; 616.33
• DOI: 10.1080/00365521.2021.1906316
• Languages: English
• ISSNs: 0036-5521

Abstract

Abstract: Background: Immunotherapy, targeting programmed death-1 (PD-1) enhances antitumor T-cell activity in patients with malignancies. Blocking PD-1 or its ligand may lead to fulminant colitis as serious adverse event in these patients. Since little is known of the presence and role of PD-1 + T cells in colitis of different etiologies, we determined PD-1 + T cells in mucosal specimens of patients with inflammatory bowel disease, infectious colitis (InfC), immunotherapy-related colitis (ImC) and healthy controls (HC). Methods: Newly diagnosed patients with ulcerative colitis (UC, n = 73), Crohn's disease (CD, n = 50), InfC ( n = 5), ImC ( n = 8) and HC ( n = 8) were included. Baseline inflamed colonic biopsies were studied with immunohistochemistry and flowcytometry. Results: Using immunohistochemistry, PD-1 was not present on lymphocytes in the epithelium of all patients, nor in HC. The percentage PD-1 + of all lymphocytes in the lamina propria was 40% in UC, 5% in InfC, 3% in ImC and 0% in HC. Flowcytometry showed significant higher percentages of PD-1 + T cells in inflamed biopsy specimens of UC patients (22%) compared to all other groups: CD patients (13%), InfC (12%), ImC (5%) and HC (6%). Conclusion: There are relevant differences in distribution and frequencies of mucosal PD-1 + T-cell subsets in patients with UC, CD, InfC and ImC, supporting the hypothesis that these types of colitis are driven by different immunological pathways. The increased numbers of PD-1 + and PD-L1 + lymphocytes in the colonic mucosa of UC patients suggest that the PD-1/PD-L1 pathway might be more activated in UC than in CD.